Endocrinology, diabetes & metabolism · 2026
Real-Time Continuous Glucose Monitoring Use and Kidney Function Among People With Diabetes and CKD or At-Risk for CKD.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McGrath Nathan G, Skaugen John, Johnson Bruce, Hage Chadi A, Alasfar Sami, McCullough Ann E, Sigler Rachel, Sanchez Pablo G, Coster Janalee N, Marayati Firas, Vikram Holenarasipur R, Haidar Ghady, Bartholow Tanner
Аннотация
INTRODUCTION: Continuous glucose monitoring (CGM) use may benefit people with diabetes and chronic kidney disease (CKD). In this propensity-matched, retrospective analysis using Truveta-provided de-identified EMR data, changes in kidney function and glycemia were compared between cohorts starting real-time CGM (RT-CGM) use and CGM non-users (No CGM).
METHODS: Adults with type 1 or type 2 diabetes, treated with any insulin, with estimated glomerular filtration rate (eGFR) of 15-89 mL/min/1.73 m2 were included. Changes in eGFR, albumin-to-creatinine ratio (ACR), and HbA1c between baseline and 3-year follow-up were assessed.
RESULTS: RT-CGM initiation (N = 518 per cohort) was associated with a significantly slower decline in eGFR compared to No CGM. There was no significant difference in change in ACR between the groups (N = 138 per cohort). RT-CGM use (N = 461 per cohort) was associated with a significantly greater decrease in HbA1c compared to No CGM.
CONCLUSIONS: These findings support RT-CGM initiation among people with diabetes and CKD or at risk for CKD.
METHODS: Adults with type 1 or type 2 diabetes, treated with any insulin, with estimated glomerular filtration rate (eGFR) of 15-89 mL/min/1.73 m2 were included. Changes in eGFR, albumin-to-creatinine ratio (ACR), and HbA1c between baseline and 3-year follow-up were assessed.
RESULTS: RT-CGM initiation (N = 518 per cohort) was associated with a significantly slower decline in eGFR compared to No CGM. There was no significant difference in change in ACR between the groups (N = 138 per cohort). RT-CGM use (N = 461 per cohort) was associated with a significantly greater decrease in HbA1c compared to No CGM.
CONCLUSIONS: These findings support RT-CGM initiation among people with diabetes and CKD or at risk for CKD.